A number of other equities research analysts also recently issued reports on CRSP. Roth Capital upped their price objective on Crispr Therapeutics from $65.00 to $100.00 in a research report on Tuesday, November 19th. Chardan Capital restated a “buy” rating and set a $72.50 price objective on shares of Crispr Therapeutics in a research report on Monday, November 18th. Wells Fargo & Co restated a “buy” rating on shares of Crispr Therapeutics in a research report on Friday, December 6th. Goldman Sachs Group upped their price objective on Crispr Therapeutics from $52.00 to $75.00 and gave the company a “neutral” rating in a research report on Tuesday, November 19th. Finally, Oppenheimer upped their target price on Crispr Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a research note on Monday, November 25th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and twelve have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $75.95.
Shares of CRSP stock opened at $58.39 on Thursday. Crispr Therapeutics has a 1 year low of $29.34 and a 1 year high of $74.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32. The stock’s 50 day simple moving average is $63.82 and its two-hundred day simple moving average is $52.42. The company has a market cap of $3.22 billion, a PE ratio of -126.93 and a beta of 3.20.
Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The business had revenue of $211.93 million for the quarter, compared to the consensus estimate of $6.32 million. Equities research analysts expect that Crispr Therapeutics will post 0.65 EPS for the current year.
In other news, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $62.00, for a total transaction of $465,000.00. Following the transaction, the director now owns 7,500 shares of the company’s stock, valued at $465,000. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, President Rodger Novak sold 33,618 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the transaction, the president now directly owns 33,618 shares in the company, valued at approximately $2,353,260. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 56,118 shares of company stock worth $3,620,760. Insiders own 21.40% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Farmers & Merchants Trust Co of Chambersburg PA bought a new position in Crispr Therapeutics in the fourth quarter worth approximately $26,000. Webster Bank N. A. bought a new position in Crispr Therapeutics in the fourth quarter worth approximately $26,000. NEXT Financial Group Inc grew its stake in Crispr Therapeutics by 915.0% in the third quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock worth $25,000 after purchasing an additional 549 shares in the last quarter. US Bancorp DE grew its stake in Crispr Therapeutics by 553.7% in the second quarter. US Bancorp DE now owns 621 shares of the company’s stock worth $29,000 after purchasing an additional 526 shares in the last quarter. Finally, Coastal Investment Advisors Inc. bought a new position in Crispr Therapeutics in the third quarter worth approximately $26,000. 49.83% of the stock is currently owned by hedge funds and other institutional investors.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.